title: Improvement of neurological symptoms and memory and emotional status in a case of seronegative Sneddon syndrome with cyclophosphamide.
abstract: Sneddon syndrome (SS) is characterized by livedo racemosa, recurrent ischemic strokes, and often progressive vascular dementia. Treatment options for SS center on either anticoagulation or immunosuppression to prevent strokes and to dissipate the skin findings, with these modalities based historically on the presence or absence of antiphospholipid antibodies (APA) respectively. However, few effective treatments have been reported to reverse the cognitive decline in SS. We report a case of a woman with seronegative SS (absence of APA) with cognitive decline who demonstrated objective and subjective improvements in her memory and emotional functioning after treatment with cyclophosphamide.
authors.affiliation: Department of Neurology, Baylor College of Medicine, Houston, TX 77030, United States.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Hannon
authors.forename: Sheng-Han
authors.initials: SH
authors.lastname: Kuo
authors.forename: Adriana M
authors.initials: AM
authors.lastname: Strutt
authors.forename: Michele K
authors.initials: MK
authors.lastname: York
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Kass
mesh_terms: D001288:Attention / Q000187:drug effects; D002533:Cerebral Angiography; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004644:Emotions / Q000187:drug effects*; D056344:Executive Function / Q000187:drug effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007858:Learning; D018810:Magnetic Resonance Angiography; D008279:Magnetic Resonance Imaging; D008297:Male; D008568:Memory / Q000187:drug effects*; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology*; D009483:Neuropsychological Tests; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology; D018860:Sneddon Syndrome / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D014706:Verbal Learning
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide
references.citation: Neurology. 1990 Mar;40(3 Pt 1):464-7
references.pmid: 2314589
references.citation: Am J Surg Pathol. 1995 Apr;19(4):448-53
references.pmid: 7694946
references.citation: Medicine (Baltimore). 1999 Jul;78(4):209-19
references.pmid: 10424203
references.citation: Stroke. 1995 Mar;26(3):492-5
references.pmid: 7886731
references.citation: J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):542-4
references.pmid: 12640088
references.citation: Br J Dermatol. 1965 Apr;77:180-5
references.pmid: 14278790
references.citation: Intern Med. 1996 Aug;35(8):668-73
references.pmid: 8894746
references.citation: Eur Neurol. 2002;48(3):126-32
references.pmid: 12373028
references.citation: Neurology. 1995 Mar;45(3 Pt 1):557-60
references.pmid: 7898716
references.citation: Mayo Clin Proc. 1999 Jan;74(1):57-61
references.pmid: 9987534
references.citation: Stroke. 1996 May;27(5):1008-10
references.pmid: 8623093
references.citation: Arch Neurol. 1997 Jan;54(1):53-60
references.pmid: 9006414
references.citation: Clin Rheumatol. 2005 Feb;24(1):79-82
references.pmid: 15340865
references.citation: Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jul-Sep;14(3):197-204
references.pmid: 11513104